Composite endpoints in COPD: clinically important deterioration in the UPLIFT trial

[1]  F. Martinez,et al.  Benefits of glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) in improving lung function and reducing exacerbations in patients with moderate-to-very severe COPD: a pooled analysis of the PINNACLE studies , 2020, Respiratory Research.

[2]  A. D’Urzo,et al.  Comparison of glycopyrronium versus tiotropium on the time to clinically important deteriorations in patients with COPD: a post-hoc analysis of randomized trials , 2018, npj Primary Care Respiratory Medicine.

[3]  T. Greulich,et al.  Indacaterol/glycopyrronium reduces the risk of clinically important deterioration after direct switch from baseline therapies in patients with moderate COPD: a post hoc analysis of the CRYSTAL study , 2018, International journal of chronic obstructive pulmonary disease.

[4]  Dave Singh,et al.  Reduction in clinically important deterioration in chronic obstructive pulmonary disease with aclidinium/formoterol , 2017, Respiratory Research.

[5]  A. Anzueto,et al.  The effect of indacaterol/glycopyrronium versus tiotropium or salmeterol/fluticasone on the prevention of clinically important deterioration in COPD , 2017, International journal of chronic obstructive pulmonary disease.

[6]  Dave Singh,et al.  Prevention of clinically important deteriorations in COPD with umeclidinium/vilanterol , 2016, International journal of chronic obstructive pulmonary disease.

[7]  M. Decramer,et al.  Defining a COPD composite safety endpoint for demonstrating efficacy in clinical trials: results from the randomized, placebo-controlled UPLIFT® trial , 2016, Respiratory Research.

[8]  M. Decramer,et al.  Chronic Obstructive Pulmonary Diseases : Journal of the COPD Foundation Effects of Tiotropium on Exacerbations in Patients with COPD with Low or High Risk of Exacerbations : A Post-Hoc Analysis from the 4-Year UPLIFT ® Trial , 2015 .

[9]  P. Jones.  Estimation and application of the minimum clinically important difference in COPD. , 2014, The Lancet. Respiratory medicine.

[10]  F. Martinez,et al.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. , 2007, American journal of respiratory and critical care medicine.

[11]  C. Tantucci,et al.  Lung function decline in COPD , 2012, International journal of chronic obstructive pulmonary disease.

[12]  Marie Westwood,et al.  Relationship between FEV1 change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review , 2011, Respiratory research.

[13]  D. Halpin,et al.  Defining Disease Modification in Chronic Obstructive Pulmonary Disease , 2009, COPD.

[14]  M. Decramer,et al.  A 4-year trial of tiotropium in chronic obstructive pulmonary disease. , 2008, The New England journal of medicine.

[15]  M. Pistolesi,et al.  Outcomes for COPD pharmacological trials: from lung function to biomarkers , 2008, European Respiratory Journal.

[16]  J. Donohue.  Minimal Clinically Important Differences in COPD Lung Function , 2005, COPD.

[17]  M. Decramer,et al.  Clinical Trial Design Considerations in Assessing Long‐Term Functional Impacts of Tiotropium in COPD: The Uplift Trial , 2004, COPD.

[18]  Nick Freemantle,et al.  Composite outcomes in randomized trials: greater precision but with greater uncertainty? , 2003, JAMA.

[19]  Hilde van der Togt,et al.  Publisher's Note , 2003, J. Netw. Comput. Appl..